Harris Williams & Co. Advises Synowledge on its Sale to BioClinica, Inc.

September 21, 2015

Harris Williams & Co., a preeminent middle market investment bank focused on the advisory needs of clients worldwide, announces the sale of Synowledge to BioClinica, Inc. (BioClinica), a specialty clinical trials services and technology provider. Synowledge provides drug safety, regulatory affairs and related IT services to small, mid and large-sized pharmaceutical, biotechnology and medical device companies. The company delivers services through a global workforce of more than 500 employees who provide around-the-clock expertise and support remotely or onsite. The transaction was led on behalf of Synowledge by Cheairs Porter, Paul Hepper and Nick Owens of Harris Williams & Co.’s Healthcare & Life Sciences (HCLS) Group.

“Sankesh Abbhi founded Synowledge in 2006, and the company has since generated rapid growth by providing best-in-class drug safety and regulatory affairs solutions to its clients through its hybrid model of 24x7 support remotely or onsite,” said Paul Hepper, a director at Harris Williams & Co. “The acquisition of Synowledge expands BioClinica’s solutions into another important area for clients.”

Synowledge is a specialized Pharmacovigilance, Regulatory Affairs and IT services provider that assists and enables small, medium and large life sciences organizations to satisfy their global regulatory requirements. The Synowledge team consists of highly qualified and skilled experts who are committed to helping companies meet and exceed the challenging demands of the R&D lifecycle. The company’s comprehensive outsourcing solutions cover all therapeutic areas and combine the unique strengths and knowledge of industry leading experts. Synowledge’s commitment to quality allows the company to deliver accurate, consistent and robust solutions to the life sciences industry. Synowledge was founded in 2006 and is headquartered in Miami, Florida.  Synowledge has global offices in North America, Europe, India and Japan.

BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica’s experience spans three decades and includes thousands of studies in all therapeutic areas.  The company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.

Harris Williams & Co. (www.harriswilliams.com), a member of The PNC Financial Services Group, Inc. (NYSE:PNC), is a preeminent middle market investment bank focused on the advisory needs of clients worldwide.  The firm has deep industry knowledge, global transaction expertise and an unwavering commitment to excellence. Harris Williams & Co. provides sell-side and acquisition advisory, restructuring advisory, board advisory, private placements and capital markets advisory services.

Harris Williams & Co.’s HCLS Group has experience across a broad range of sectors, including healthcare IT; managed care and cost containment services; alternate site care; medical devices, products and distribution; outsourced clinical and practice management services; and outsourced pharma services. For more information on the HCLS Group and other recent transactions, visit the HCLS Group’s section of the Harris Williams & Co. website.

Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams & Co. Ltd, which is authorized and regulated by the Financial Conduct Authority.  Harris Williams & Co. is a trade name under which Harris Williams LLC and Harris Williams & Co. Ltd conduct business.